GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » EV-to-EBITDA

PharmaCyte Biotech (PharmaCyte Biotech) EV-to-EBITDA : 6.18 (As of May. 03, 2024)


View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmaCyte Biotech's enterprise value is $-25.43 Mil. PharmaCyte Biotech's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was $-4.12 Mil. Therefore, PharmaCyte Biotech's EV-to-EBITDA for today is 6.18.

The historical rank and industry rank for PharmaCyte Biotech's EV-to-EBITDA or its related term are showing as below:

PMCB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -50.93   Med: -4.38   Max: 6.18
Current: 6.18

During the past 13 years, the highest EV-to-EBITDA of PharmaCyte Biotech was 6.18. The lowest was -50.93. And the median was -4.38.

PMCB's EV-to-EBITDA is ranked better than
54.29% of 466 companies
in the Biotechnology industry
Industry Median: 9.15 vs PMCB: 6.18

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), PharmaCyte Biotech's stock price is $2.16. PharmaCyte Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.200. Therefore, PharmaCyte Biotech's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


PharmaCyte Biotech EV-to-EBITDA Historical Data

The historical data trend for PharmaCyte Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech EV-to-EBITDA Chart

PharmaCyte Biotech Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.83 -10.28 -11.29 8.76 4.40

PharmaCyte Biotech Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.87 4.40 7.34 8.86 6.08

Competitive Comparison of PharmaCyte Biotech's EV-to-EBITDA

For the Biotechnology subindustry, PharmaCyte Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's EV-to-EBITDA falls into.



PharmaCyte Biotech EV-to-EBITDA Calculation

PharmaCyte Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-25.432/-4.118
=6.18

PharmaCyte Biotech's current Enterprise Value is $-25.43 Mil.
PharmaCyte Biotech's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaCyte Biotech  (NAS:PMCB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

PharmaCyte Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.16/-1.200
=At Loss

PharmaCyte Biotech's share price for today is $2.16.
PharmaCyte Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.200.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


PharmaCyte Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaCyte Biotech (PharmaCyte Biotech) Business Description

Traded in Other Exchanges
N/A
Address
3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. It is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb director 100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen director 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K director
Carlos Trujillo director, officer: CFO 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner director, officer: Chairman, CEO, Pres and GC 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree director, officer: Chief Science Officer 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099